Literature DB >> 9677161

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

J Balzarini1, L Naesens, E Verbeken, M Laga, L Van Damme, M Parniak, L Van Mellaert, J Anné, E De Clercq.   

Abstract

BACKGROUND: Thiocarboxanilide UC-781 is a highly potent and selective non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1, which also has virucidal properties. Recent studies have shown that UC-781 would seem an ideal candidate for application as a vaginal virucide.
OBJECTIVE: To investigate the antiviral potency and stability of UC-781 in a lipophilic gel formulation.
METHODS: UC-781 was formulated in replens gel at different concentrations and administered intravaginally to rabbits at 5% in replens gel for 10 days. UC-781 was also exposed to temperatures of 4, 37 and 50 degrees C, and to low pH (6.0, 4.3, 2.0 and 1.2). A number of microorganisms were exposed in culture to serial dilutions of UC-781.
RESULTS: The drug was stable under low pH conditions and did not lose its antiviral potency upon 4 h exposure to pH 3.5 (the estimated vaginal pH). UC-781 can be easily formulated into a lipophilic gel (replens; up to 5%) and proved fully stable at 50 degrees C for 30 days. There was no effect on the growth of microorganisms (i.e., Candida and Lactobacillus strains) that are present in the vaginal flora. Neither systemic side-effects, nor local inflammation or damage of the vaginal mucosa or epithelium were observed in rabbits to which 5% UC-781 in replens gel had been administered. UC-781, formulated as 0.5, 0.2 and 0.05% replens gel, and UC-38, alpha-APA and zidovudine, formulated as 0.5 or 0.2% replens gel, were effective in protecting CEM cells in the very beginning against productive HIV-1 replication. This points to an efficient diffusion of the drugs from the lipophilic gel to the hydrophilic culture medium. However, subsequent subcultivations at a dilution rate of 1:10 every 3-4 days resulted in a rapid breakthrough of virus with all drugs except UC-781 in its 0.5 and 0.2% gel formulation. These cultures were fully protected against HIV-1 and remained completely cleared from virus for at least 10 subcultivations.
CONCLUSIONS: The virus that emerged under 0.05% UC-781 remained highly sensitive to the NNRTI, including UC-781, in cell culture, suggesting a lack of resistance development under our experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9677161     DOI: 10.1097/00002030-199810000-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  29 in total

1.  An Update on Vaginal Microbicides.

Authors:  Christine Mauck; Gustavo Doncel
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

2.  Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Authors:  Phalguni Gupta; Deena Ratner; Ming Ding; Bruce Patterson; Lisa C Rohan; Todd A Reinhart; Velpandi Ayyavoo; Xioli Huang; Dorothy L Patton; Bharat Ramratnam; Alexander M Cole
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

3.  Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

Authors:  D L Patton; Y T Cosgrove Sweeney; J E Balkus; L C Rohan; B J Moncla; M A Parniak; S L Hillier
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

Review 4.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

5.  In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Authors:  Charlene S Dezzutti; V Nicole James; Artur Ramos; Sharon T Sullivan; Aladin Siddig; Timothy J Bush; Lisa A Grohskopf; Lynn Paxton; Shambavi Subbarao; Clyde E Hart
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system.

Authors:  Phalguni Gupta; Kelly B Collins; Deena Ratner; Simon Watkins; Gregory J Naus; Daniel V Landers; Bruce K Patterson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Self-delivery multifunctional anti-HIV hydrogels for sustained release.

Authors:  Jiayang Li; Xinming Li; Yi Kuang; Yuan Gao; Xuewen Du; Junfeng Shi; Bing Xu
Journal:  Adv Healthc Mater       Date:  2013-04-25       Impact factor: 9.933

8.  PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture.

Authors:  Humberto H Lara; Liliana Ixtepan-Turrent; Elsa N Garza-Treviño; Cristina Rodriguez-Padilla
Journal:  J Nanobiotechnology       Date:  2010-07-13       Impact factor: 10.435

9.  RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.

Authors:  Yonghou Jiang; Baoping Tian; Mohammed Saifuddin; Michael B Agy; Peter Emau; J Scott Cairns; Che-Chung Tsai
Journal:  AIDS Res Ther       Date:  2009-11-05       Impact factor: 2.250

10.  Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.

Authors:  Ana Ventuneac; Alex Carballo-Diéguez; Ian McGowan; Robert Dennis; Amy Adler; Elena Khanukhova; Charles Price; Terry Saunders; Chomchay Siboliban; Peter Anton
Journal:  AIDS Behav       Date:  2009-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.